



## Press Release For Immediate Release

### Immunic Therapeutics One of Featured Companies at Mid-Atlantic Bio 2009

**Rockville, MD, November 4, 2009** — Immunic Therapeutics, Inc. ("ITI") reported today that the Company was one of the companies featured in the Emerging Growth Track at this year's Mid-Atlantic Bio Conference. Dr. Bill Hearl, President and CEO of Immunic Therapeutics, Inc., gave the 10 minute presentation to a full room of investors and attendees of the 2009 event. The ITI Corporate presentation emphasized the business strategy of the Company which is to expedite the clinical development of LAMP-vax Technology by focusing on the high-value allergy market. The Company's first vaccine immunotherapy in development targets Japanese red cedar, the #1 allergen in Japan. It is the goal of ITI to finish Phase I and Phase II of the clinical evaluation of JRC-LAMP-vax by the end of 2011, achieving three key valuation and performance milestones. The presentation concluded with an overview of the Company's investment needs and exit strategy reflecting a high value, high return investment opportunity.

Following the presentation, Dr. Hearl said, "The Mid-Atlantic Bio Conference is one of the premier events for our industry in this region. It creates a tremendous venue for large and small biotech companies to interact and explore collaboration opportunities. It is a really well-run event." He went on to say that he was pleased that ITI was selected as one of the featured companies and looks forward to future Mid-Atlantic Bio conferences.

# # #

#### About Mid-Atlantic Bio

Mid-Atlantic Bio is co-hosted by the MdBio Division of the Tech Council of Maryland (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit [www.midatlanticbio.org](http://www.midatlanticbio.org).

#### About Immunic Therapeutics

Immunic Therapeutics, Inc. ("ITI") is a privately held clinical stage biotechnology company headquartered in Rockville, Maryland with offices in Baltimore & Lancaster, PA. ITI is developing next generation vaccines based on patented LAMP Technology. Our LAMP-vax™ platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP construct(s) have been validated in human clinical trials (Geron's GRNVAC1 cancer) and have been applied to a wide breadth of targets including infectious disease (Influenza, HIV, West Nile Virus, Dengue and others), allergy and cancer. More information about ITI and LAMP technology can be obtained from [www.immunomix.com](http://www.immunomix.com).

*This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI's technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors.*

**CONTACT:**

Bill Hearl, Ph.D., President & CEO  
Immunomic Therapeutics, Inc.  
240-731-5232  
bhearl@immunomictherapeutics.com